Focus on growth, investments; capacity in Biologics a growth driver: Syngene Intl
Money Control-24/01/2018. With a focus on future business growth, the company has done lot of investments – building new infrastructure and capabilities and they are now ready, said Hunt...
We are in the process of implementing a $200 million growth capex plan to expand capacity and extend capabilities
Globally, we anticipate to see a healthy demand for high quality scientific services, not just in the pharma and biotechnology industries but also in other research focused industries...